TL;DR
PharmEasy-owned Thyrocare exits radiology and gives a nod for sale of 100% stake in Nueclear Healthcare Ltd (NHL) to Trovera Healthcare for around Rs. 141.4 Cr.
Deal structure: Rs. 81.9 Cr cash plus 42,500 Trovera CCPS worth Rs. 59.5 Cr (about 4.5% stake, convertible 1:1 into equity). Source: HDFC SKY2
The move marks Thyrocare’s exit from capital intensive radiology to focus on core pathology operations.
What Happened: Thyrocare Exits Radiology
Thyrocare exits radiology and it has approved the sale of its entire shareholding in wholly owned subsidiary Nueclear Healthcare Ltd (NHL) to Trovera Healthcare Private Ltd for approximately Rs. 141.4 Cr.
The transaction is about transfer of 1.11 Cr equity shares (100% of NHL) to Trovera and Thyrocare will receive Rs. 81.9 Cr in cash and 42,500 compulsorily convertible preference shares (CCPS) worth Rs. 59.5 Cr.
The CCPS are priced at Rs. 14,000 each and represent around 4.5% of Trovera’s share capital, convertible into equity shares in a 1:1 ratio.
Trovera was incorporated in June 2026 and is founded by Surana Group of Hospitals CEO Dr Prince Surana, with plans to operate in healthcare and diagnostic services.
Thyrocare expects to complete the transaction on or before November 30, 2026, subject to shareholder and other applicable approvals.
Deal Structure and Numbers
1. Total consideration: Rs. 141.4 Cr approx for 100% of NHL.
2. Cash component Rs. 81.9 Cr, subject to working capital adjustments under the share purchase agreement.
3. Stock component: 42,500 Trovera CCPS valued at Rs. 59.5 Cr (face value Rs. 10, premium Rs. 13,990; issue price Rs.14,000).
4. Property purchase: Thyrocare will acquire Gurugram and Hyderabad lab properties from NHL for Rs. 20.59 Cr to continue operating its diagnostic centres.
5.Timeline: Share purchase agreement yet to be executed; completion expected by November 30, 2026.
Why Thyrocare Is Exiting Radiology
1.Capital Intensity:
The radiology and diagnostic imaging business of NHL requires continuous investment in equipment, technology, maintenance and infrastructure. This looks like a major investment despite poor growth.
2.Strategic Focus:
Divestment allows Thyrocare to focus capital and management attention on its core pathology business which has higher growth and margins. The scope is higher and hence the strategy.
3.Underperformance:
The radiology vertical was not growing and this encouraged Thyrocare to withdraw its interest from the radiology segment. Thyrocare was not keen to invest further. Hence the search for a partner who will invest and grow the business.
4.Earlier plans:
The plans to divest NHL and exit radiology from Thyrocare was first reported in September 2024 with evaluation of demerger options through slump sale or business transfer.
Financial Performance: NHL and Thyrocare
Nueclear Healthcare (NHL) FY26 Metrics
Turnover: Rs. 44.62 Cr, contributing to 5.38% of Thyrocare’s consolidated turnover in FY 26.
Net worth Rs. 83.55 Cr which is 14.27% of Thyrocare’s consolidated net worth.
Profitability: Profit after tax (PAT) margin of 10.9% of revenue in FY26, versus Thyrocare’s standalone PAT margin of 19.2%.
Thyrocare Q1 FY27 Performance
Consolidated net profit: Rose 34% YoY to Rs. 51.3 Cr in Q1 FY27.
Operating revenue: Increased 24.4% YoY to Rs.240 Cr in Q1 FY27, driven by 26% growth in the pathology segment.
Radiology segment: reported 4% YoY decline in operating revenue to Rs. 13.48 Cr in Q1 FY27 as the company exited loss making centers.
Source: Inc42
What This Means for Investors
1. Portfolio clarity:
It gives signals to exit from a slower growing, capital intensive vertical. And this simplifies Thyrocare’s business model and sharpens focus on high margin pathology.
2. Cash plus equity upside:
Liquidity gets a boost with Rs.82 Cr cash. Trovera stake provides optional upside, if radiology business scales under new ownership.
3. Operational continuity:
Thyrocare continues to maintain control of key diagnostic center locations. The new acquisitions of properties in Gurugram and Hyderabad will also affect the number.
4. Risk watch:
Transaction subject to shareholder approval Execution timing and Trovera's ability to scale radiology are key watch items.
Conclusion
Thyrocare exits radiology and this sale of Nueclear Healthcare for Rs. 141.4 Cr is a clean strategic pivot: exit a slower growing, capital heavy radiology vertical and double down on a faster growing, higher margin pathology core. The cash and equity consideration, plus the purchase of key lab properties, balances immediate liquidity with optionality and operational continuity.
For investors, the move simplifies the equity story while leaving a small stake in the radiology upside via Trovera.
FAQs
What is the total value of Thyrocare’s sale of Nueclear Healthcare?
The deal is valued at approximately Rs. 141.4 Cr for 100% of NHL, comprising Rs. 81.9 Cr cash and Rs. 59.5 Cr in Trovera CCPS.
How is the consideration of Thyrocare selling radiology structured?
Thyrocare will receive nearly Rs. 81.9 Cr in cash (subject to working capital adjustments) and 42,500 Trovera CCPS worth Rs. 59.5 Cr which is priced at Rs. 14,000 each.
Why is Thyrocare exiting the radiology business?
Radiology is capital intensive and underperforming relative to core pathology; the exit allows Thyrocare to focus capital and management on higher growth, higher margin operations.
What percentage of Thyrocare’s turnover did NHL contribute in FY26?
NHL reported turnover of Rs. 44.62 Cr in FY26, which was 5.38% of Thyrocare’s consolidated turnover.
What else is Thyrocare doing alongside this sale?
Thyrocare is buying NHL’s Gurugram and Hyderabad lab properties for Rs. 20.59 Cr to continue operating its diagnostic centres at those locations.
When is the transaction expected to close?
Thyrocare expects to complete the transaction on or before November 30, 2026, subject to shareholder and other applicable approvals.
